Bladder Cancer
Precancerous Cervical Dysplasia

Precancerous Cervical Dysplasia

Cervical High-grade Squamous intraepithelial Lesion (HSIL) is a disease of the cervical epithelium, also known as moderate- and high-grade cervical intraepithelial neoplasia (CIN2 and CIN3). HSIL is caused by persistent infection with the cancer-causing human papillomavirus (HPV). HPV infection is common in sexually active women, with a lifetime risk of infection of 75%¹. Most HPV infections are in an incubation period, and most infected individuals clear the virus on their own within three years² . In non-cleared individuals, persistent oncogenic HPV infection may lead to HSIL and invasive cervical cancer.

1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3 8.
2. Ferenczy A, Franco EL. Prophylactic human papillomavirus vaccines: potential for sea change. Expert Rev. Vaccines 2007; 6(4 ): 511-525.

Unmet Clinical Needs

Patients with cervical precancerous lesions are mainly treated with traditional surgical methods. Safe and effective alternate treatment options are urgently needed.

Limitations of Traditional Surgical Treatment

Treatment
Adverse Effects
Market Needs
  • Cervix circumcision
  • Bleeding, infection
  • Patients requiring cervical function preserving non-surgical treatment
  • Cold-knife conical resection
  • Cervical organic damage
  • No non-surgical treatment for cervical precancerous lesions in the world
  • Premature birth, miscarriage​

Asieris Solution

APL-1702 (Cevira®)

APL-1702 is a drug-device combination photodynamic therapy product.

For non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL) caused by any HPV subtypes.

Easy to administer and absorb, not restricted by medical facilities and environment., and with good patient compliance.

High Market Demand

The large base of patients with cervical precancerous lesions demand safe and effective treatment options.
2020-2030 HSIL Patients Worldwide
2020-2030 HSIL Patients in China
2020
16 million
14 million
2030
2020
2.1 million
2.2 million
2030

Data source: Frost & Sullivan

Bladder Cancer